Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.31 |
| ▸ | ABAT | P80404 | 1/20 | 0.31 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860208 | 0.78 | KCNH2 (0.41) | KDM4EALDH1A1FFAR1FFAR4 | |
| SCHEMBL4764093 | 0.76 | KDM4E (0.35) | KDM4EALDH1A1HCAR2TLR7RAB9A | |
| SCHEMBL20456511 | 0.75 | P4HA1 (0.46) | ALDH1A1L3MBTL1HCAR2 | |
| SCHEMBL18810226 | 0.75 | KDM4E (0.40) | KDM4EALDH1A1L3MBTL1KCNJ1PTGS2 | |
| SCHEMBL2562582 | 0.75 | HRH3 (0.40) | KDM4EALDH1A1ALDH5A1ABATFFAR1 | |
| SCHEMBL24300768 | 0.73 | KDM4E (0.36) | KDM4EALDH1A1L3MBTL1TLR7ASIC3 | |
| SCHEMBL3542402 | 0.73 | ADRA2A (0.41) | KDM4EALDH1A1L3MBTL1RAB9A | |
| SCHEMBL16287685 | 0.72 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1KCNJ1PTGS2 | |
| SCHEMBL30409880 | 0.72 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1KCNJ1PTGS2 | |
| SCHEMBL26001309 | 0.71 | KDM4E (0.37) | KDM4EALDH1A1L3MBTL1KCNJ1ALDH5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-01-10 | — | — | US | disclosed |
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3512855-B1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-110062759-B | Fused 1, 4-oxazepine as BET protein degrading agent | 密执安大学评议会 | 2022-05-24 | — | — | CN | disclosed |
| CN-109071562-B | Fused 1, 4-oxazepine and related analogs as BET bromodomain inhibitors | 密执安大学评议会 | 2022-03-22 | — | — | CN | disclosed |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3416969-B1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3416969-B1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3512855-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | The Regents of the University of Michigan (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3416969-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | The Regents of The University of Michigan (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2018052945-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018052945-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2017142881-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017142881-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | BRD4, BET1, BRD1 | KDM4E 67/4885ALDH1A1 2770/4885L3MBTL1 534/4885 |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KDM4E 161/4885ALDH1A1 2498/4885L3MBTL1 989/4885 |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD2 | KDM4E 161/4885ALDH1A1 2498/4885L3MBTL1 989/4885 |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | KDM4E 67/4885ALDH1A1 2770/4885L3MBTL1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.